Grifols, S.A. (NASDAQ:GRFS) Shares Purchased by Natixis Advisors LLC

Natixis Advisors LLC increased its stake in shares of Grifols, S.A. (NASDAQ:GRFS) by 40.0% in the third quarter, HoldingsChannel.com reports. The firm owned 215,667 shares of the biotechnology company’s stock after buying an additional 61,614 shares during the period. Natixis Advisors LLC’s holdings in Grifols were worth $1,915,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. B. Riley Wealth Advisors Inc. acquired a new stake in shares of Grifols in the second quarter valued at $359,000. Sei Investments Co. boosted its holdings in Grifols by 4.7% during the 2nd quarter. Sei Investments Co. now owns 2,209,547 shares of the biotechnology company’s stock valued at $13,931,000 after acquiring an additional 100,131 shares during the period. Hantz Financial Services Inc. acquired a new position in Grifols in the 2nd quarter valued at about $1,235,000. Point72 Asset Management L.P. increased its stake in Grifols by 34.4% during the second quarter. Point72 Asset Management L.P. now owns 596,845 shares of the biotechnology company’s stock worth $3,763,000 after purchasing an additional 152,700 shares during the period. Finally, Brandes Investment Partners LP lifted its position in shares of Grifols by 8.7% during the second quarter. Brandes Investment Partners LP now owns 18,596,790 shares of the biotechnology company’s stock worth $117,242,000 after purchasing an additional 1,481,924 shares in the last quarter.

Grifols Price Performance

Shares of NASDAQ GRFS opened at $8.60 on Tuesday. Grifols, S.A. has a 12-month low of $5.30 and a 12-month high of $12.15. The company has a current ratio of 2.26, a quick ratio of 0.79 and a debt-to-equity ratio of 1.11. The business’s fifty day simple moving average is $8.84 and its 200-day simple moving average is $8.09.

Wall Street Analyst Weigh In

Separately, Berenberg Bank upgraded shares of Grifols to a “strong-buy” rating in a report on Tuesday, October 29th.

About Grifols

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.